The stock surged 14.8% following the quarter, reflecting strong investor enthusiasm around COMPASS Pathways' highly statistically significant Phase III trial results for COMP360 and clear progress toward an NDA filing and launch readiness.
- Reported positive Phase III primary endpoint results demonstrating rapid and durable efficacy in treatment-resistant depression (TRD).
- NDA rolling submission is underway with completion expected in Q4 2026 and potential for accelerated FDA approval.
- Robust cash position of $433 million supports operations through launch and into 2028.
- Commercial team fully built out with extensive launch experience; active preparations for sales force recruitment and market readiness.
- Plans to leverage existing interventional psychiatry infrastructure (8,000+ sites), facilitating a smoother market entry.
Community Discussion